Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
59
EVOK Quote, Financials, Valuation and Earnings
Last price:
$11.00
Seasonality move
:
9.89%
Day range:
$11.00 - $11.00
52-week range:
$1.94 - $11.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.74x
P/B ratio:
5.64x
Volume:
--
Avg. volume:
26.2K
1-year change:
124.49%
Market cap:
$18.9M
Revenue:
$10.2M
EPS (TTM):
-$2.38
Analysts' Opinion
-
Consensus RatingEvoke Pharma, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $18.00, Evoke Pharma, Inc. has an estimated upside of 63.64% from its current price of $11.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing 100% downside risk from its current price of $11.00.
Fair Value
-
According to the consensus of 1 analyst, Evoke Pharma, Inc. has 63.64% upside to fair value with a price target of $18.00 per share.
EVOK vs. S&P 500
-
Over the past 5 trading days, Evoke Pharma, Inc. has underperformed the S&P 500 by -1.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Evoke Pharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Evoke Pharma, Inc. has grown year-over-year revenues for 12 quarters straight. In the most recent quarter Evoke Pharma, Inc. reported revenues of $4.3M.
Earnings Growth
-
Evoke Pharma, Inc. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Evoke Pharma, Inc. reported earnings per share of -$0.45.
Enterprise value:
12.5M
EV / Invested capital:
1.47x
Price / LTM sales:
1.74x
EV / EBIT:
--
EV / Revenue:
0.87x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.75x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$14M
Return On Assets:
-32.76%
Net Income Margin (TTM):
-36.23%
Return On Equity:
-104.51%
Return On Invested Capital:
-51.69%
Operating Margin:
-26.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.3M | $8.6M | $14.4M | $2.7M | $4.3M | |
| Gross Profit | $4M | $8.3M | $14M | $2.6M | $4.2M | |
| Operating Income | -$7.3M | -$5.9M | -$5.2M | -$1.3M | -$1.1M | |
| EBITDA | -$7.3M | -$5.9M | -$5.2M | -$1.3M | -$1.1M | |
| Diluted EPS | -$27.31 | -$11.09 | -$2.38 | -$0.94 | -$0.45 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $11.6M | $13.3M | $7.8M | $14M | $15.5M | |
| Total Assets | $11.7M | $13.4M | $7.9M | $14.2M | $15.6M | |
| Current Liabilities | $1.4M | $1.9M | $2.2M | $9.8M | $12.2M | |
| Total Liabilities | $6.9M | $7.9M | $8.7M | $9.8M | $12.3M | |
| Total Equity | $4.8M | $5.5M | -$873.8K | $4.4M | $3.4M | |
| Total Debt | $5M | $5M | $5M | $5M | $5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.4M | -$5.3M | -$3.3M | -$818.7K | -$522K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | $10.7M | $3.6M | $3M | $38.9K | |
| Free Cash Flow | -$6.4M | -$5.3M | -$3.3M | -$818.7K | -$522K | |
EVOK
Sector
Market Cap
$18.9M
$28M
Price % of 52-Week High
100%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-41.87%
-1.54%
1-Year Price Total Return
124.49%
-17.48%
Beta (5-Year)
-0.144
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$10.99
200-day SMA
Buy
Level
$5.18
Bollinger Bands (100)
Buy
Level
4.34 - 9.86
Chaikin Money Flow
Sell
Level
-108.2M
20-day SMA
Buy
Level
$10.94
Relative Strength Index (RSI14)
Buy
Level
85.15
ADX Line
Buy
Level
74.47
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$9.02
MACD (12, 26)
Buy
Level
0.44
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
172.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.8416)
Sell
CA Score
(Annual)
Level (-3.5092)
Sell
Beneish M-Score
(Annual)
Level (-1.0426)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.5909)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Stock Forecast FAQ
In the current month, EVOK has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The EVOK average analyst price target in the past 3 months is $18.00.
-
Where Will Evoke Pharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Evoke Pharma, Inc. share price will rise to $18.00 per share over the next 12 months.
-
What Do Analysts Say About Evoke Pharma, Inc.?
Analysts are divided on their view about Evoke Pharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Evoke Pharma, Inc. is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is Evoke Pharma, Inc.'s Price Target?
The price target for Evoke Pharma, Inc. over the next 1-year time period is forecast to be $18.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is EVOK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Evoke Pharma, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of EVOK?
You can purchase shares of Evoke Pharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Evoke Pharma, Inc. shares.
-
What Is The Evoke Pharma, Inc. Share Price Today?
Evoke Pharma, Inc. was last trading at $11.00 per share. This represents the most recent stock quote for Evoke Pharma, Inc.. Yesterday, Evoke Pharma, Inc. closed at $11.00 per share.
-
How To Buy Evoke Pharma, Inc. Stock Online?
In order to purchase Evoke Pharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get EVOK Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
EVOK
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
5.64x
1.82x
Price / LTM sales
1.74x
1.60x
Growth Metrics
EVOK
Sector
Revenue growth
61.41%
4.62%
Earnings growth
51.78%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.45
-$0.21
Profitability
EVOK
Sector
Profitability FY 2024
$9.9M
$3.5M
Return on invested capital
-51.69%
-31.77%
Return on assets
-32.76%
-27.96%
Return on equity
-104.51%
-37.63%
Earnings Date
Last Earnings Date
Nov
7
Next Earnings Date
Dec
26
Estimated Next Earnings Date
Mar
27
Balance Sheet
EVOK
Sector
Total cash
$11.6M
$26.3M
Short term investments
--
$25.7M
Total assets
$17.5M
$78M
Long term debt
$5M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
